Vivacelle Bio, Inc. Receives FDA Clearance to Enroll Patients into its Phase IIa Clinical Trial ...
(WorldNews Business)

CHICAGO--(BUSINESS WIRE)--Feb 15, 2019--Vivacelle Bio, Inc. today announces that the US. Food and Drug Administration (FDA) has granted it an Investigational New Drug (IND) clearance to proceed with its phase IIa clinical trial of the safety and efficacy of VBI-1. VBI-1 is a paradigm-changing cardiovascular support fluid that is designed for the treatment of patients with emergently life-threatening conditions due to blood loss and other causes of severe hypovolemia (low blood volume). The treatment of hypovolemia and raising blood pressure are essential to survival of a broad range of...